care was associated with significantly improved OS in patients with disease progression on first-line chemotherapy. 9 Moreover, ramucirumab plus paclitaxel chemotherapy significantly increased OS compared with paclitaxel alone in patients after first
Search Results
Advances in Systemic Therapy for Metastatic or Advanced Gastric Cancer
Kohei Shitara and Atsushi Ohtsu
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
Featured Updates to the NCCN Guidelines
David S. Ettinger, Douglas E. Wood, Charu Aggarwal, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, Michael Dobelbower, Scott Gettinger, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Jules Lin, Billy W. Loo Jr, Renato G. Martins, Gregory A. Otterson, Sandip P. Patel, Karen L. Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina Gregory, OCN, and Miranda Hughes
combined with bevacizumab/carboplatin/paclitaxel (ABCP) versus bevacizumab/chemotherapy for patients with metastatic nonsquamous NSCLC. 17 Median OS was 19.2 months (95% CI, 17.0–23.8) in the ABCP arm compared with 14.7 months (95% CI, 13.3–16.9) for
Oncology Research Program
scientific peer-review process and are overseen by the ORP. NCCN-sponsored studies funded through the grant mechanism are highlighted below. A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck
NCCN Guidelines® Updates: Melanoma: Cutaneous
circumstances” to “other recommended”: ► Capecitabine ► Gemcitabine + nab-paclitaxel modified schedule (category 2B) ► Gemcitabine single agent (category 2B) • FOLFIRI (preferred regimen) was removed and replaced with 5-FU ± irinotecan (useful in
Surgery for Ovarian Cancer: Rationale and Guidelines
Benjamin E. Greer, Ron E. Swensen, and Heidi J. Gray
carboplatin and paclitaxel as adjuvant treatment in early stage ovarian epithelial carcinoma: A Gynecolog Oncology Group study (Abstr 1) . Gynecol Oncol 2003 ; 88 : 156 . 9 Ayhan A Tuncer ZS Tuncer R . Is routine appendectomy beneficial in the
Epithelial Ovarian Cancer
Robert J. Morgan Jr., Ronald D. Alvarez, Deborah K. Armstrong, Barry Boston, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi J. Gray, Perry W. Grigsby, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Russell J. Schilder, Julian C. Schink, Nelson Teng, and Theresa L. Werner
disease may also undergo intraperitoneal chemotherapy, although no randomized evidence for stage II disease has been published. 61 , 63 , 64 In women with stage III cancer, survival was increased by 16 months after intraperitoneal therapy using cisplatin/paclitaxel
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Jairam Krishnamurthy, Janice Lyons, P. Kelly Marcom, Jennifer Matro, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Jessica S. Young, Jennifer L. Burns, and Rashmi Kumar
endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab, and pertuzumab until disease progression or unacceptable toxicity. The preliminary results after 52 months median follow-up show that median PFS was comparable between
New Therapies for Ovarian Cancer
David M. O’Malley
ICON7. 1 , 2 A 3-arm trial that enrolled 1,873 patients with newly diagnosed stage III–IV ovarian cancer, GOG-0218 randomly assigned patients 1:1 to carboplatin/paclitaxel followed by placebo maintenance therapy; carboplatin/paclitaxel
Metastatic Anal Carcinoma: The Role of Radiotherapy
Yi-Jen Chen
) for Anal Carcinoma recommend using 5-FU/cisplatin, carboplatin/paclitaxel, or FOLFOX (5-FU/leucovorin/oxaliplatin) as first-line treatment for MAC. 2 The recently reported randomized, international, multicenter, phase II InterAACT study found that
Gastric and Esophageal Cancers: Guidelines Updates
Presented by: Crystal S. Denlinger, Kristina A. Matkowskyj, and Mary F. Mulcahy
treatment options now exist that come on the heels of several negative phase II studies: the TyTAN trial of paclitaxel + lapatinib, 6 the GATSBY trial of trastuzumab emtansine (T-DM1) versus a taxane, 7 and the T-ACT trial of paclitaxel + trastuzumab. 8
